Calgary Stampede, Osheaga and more: A doctor's tips on heat safety, hydration and substance control for summer festivals in Canada
As of July 4, Environment Canada has issued heat warnings for southeastern Manitoba, parts of western Ontario and most of southern Ontario, including the Greater Toronto Area. In these areas, Canadians can expect to see daytime high temperatures in the low 30s, with some parts feeling up to 40 degrees with humidity.
The rest of the country might not be under a heat warning, which should allow for a comfortable start to this year's Calgary Stampede, running from July 4 to 13. But since it's summer, Canadians should still anticipate more heat later this month and in August. As the season runs its course, it's probably a good idea to think about staying safe and hydrated if you plan to have fun under the sun.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle.
While dramatically high summer temperatures might be a cause for concern, does that mean you should be skipping these outdoor celebrations altogether? Not necessarily, but it's a good idea to be cautious about what your body can handle and what you should do to prevent heat-related health problems.
"People are preoccupied with what's happening and they don't want to leave, or there are crowded conditions and it's difficult to move around, and the heat can be intense," Dr. Mike Howlett, president of the Canadian Association of Emergency Physicians, told Yahoo Canada about summer festivals in 2024. "So, a couple of things are at issue."
The Dalhousie University associate professor said for one, people need to be aware of their hydration and they should drink fluids as they spend time outside during these festivals. Additionally, festivalgoers should be concerned about heat exposure, especially as temperatures rise in Canada due to climate change.
"While hydration is important, also the amount of heat exposure and the warming up of your body temperature past what it can manage is another issue," he noted. "They're related, but not identical."
One way Howlett suggested people avoid any possible health problems during summer festivals is by taking frequent breaks, particularly from "hostile" environments: "If you're finding it extensively hot and and humid, then finding shade, finding cool areas as well as having enough fluids to drink and the ability to cool off a little bit is important."
Moreover, Howlett recognized summer festivals are often events where people consume alcohol or drugs, but he warned people to stay safe while using such substances. For instance, intoxicants can sometimes make it easier for issues like heat exhaustion, heat stroke and dehydration to happen.
Older adults and younger children should also take higher precautions, since they likely don't have as much resilience to dehydration and heat than other people. Additionally, Howlett urged people who have underlying medical problems, such as diabetes, heart or lung disease, kidney problems or other health issues, should also be more careful about taking breaks and being hydrated.
Finally, he recommended people wear loose-fitting light clothing, use hats and apply sunscreen if they're planning on spending time at an outdoors festival: "It's better to make a plan where you're going to take breaks out of the sun, where you're going to have lots of fluids, use hats and if you have medical problems, be more careful and avoid substances that are intoxicants that lower your ability to pay attention to what's happening."
Glen Kenny, a University of Ottawa professor and director of the Human and Environmental Physiology Research Unit, previously told Yahoo Canada that heat is a "silent killer." Howlett reiterated that sentiment, noting heat-related health problems can easily "sneak up on people."
Howlett added that heat stroke is basically an extreme version of heat exhaustion, where "your body has totally lost its ability to control its core temperature." In that case, your temperature will rise dramatically, leading to serious ailments like coma or seizures.
"For every 10 minutes that you're not treated, it increases your death rate," he warned. "So, it's extremely important not to get to that state in the first place. Before that happens, you want to pay attention to things like if you're excessively tired and really worn out and fatigued more than usual for yourself, if you're starting to get dizzy and lightheaded."
According to the Canadian Red Cross, heat-related health problems arise when someone is dehydrated — and they can happen to anyone who stays in the heat or under the sun for too long. There are key differences between heat exhaustion and heat stroke that everyone should recognize.
Signs and symptoms of heat exhaustion and heat stroke
Heat exhaustion
Heat stroke
Skin
Moist, warm
Dry, hot
Physical
Headache, weakness,
exhaustion, nausea,
vomiting, fainting
Seizures, coma,
severe headache
Mental
Anxiety, dizziness
Altered behaviour,
irritable, aggressive,
bizarre
Breathing
Normal
Rapid, shallow
"If those things are happening, you should not go back out until it's settled over, which is not an hour or two," Howlett said. "It's like two or three days before you should go back out again."
Moreover, the Canadian Red Cross indicated you should immediately call 9-1-1 if someone has heat exhaustion if they're nauseous, vomiting, fainting, dizzy and have anxiety. If they have heat stroke and present any of the listed symptoms, call emergency services.
While alcohol is a fluid, you don't want to make the mistake that it's keeping you hydrated: "Anything with alcohol in it will tend to dehydrate you," Howlett shared.
While consuming alcohol, the body releases an antidiuretic hormone called vasopressin, according to Cleveland Clinic. This hormone works with your kidneys to help balance your body's fluids. However, alcohol is also a diuretic, which means it increases your need to urinate and, in turn, lose fluid.
The best way to counteract this is to stay on top of how much water you're drinking. While a common recommendation is to drink around eight glasses of water a day, the actual required amount of water someone should drink daily depends on the person.
While drinking alcohol, Cleveland Clinic dietitian Julia Zumpano suggested drinking eight to 12 ounces of water for every alcoholic beverage you consume. That will help slow your alcohol intake and mitigate the effects of the next morning's hangover.
When it comes to drugs, there are some that simply don't mix well with the sun. Howlett shared substances like ecstasy, cocaine or others within the amphetamines group can cause their own heat-related health problems. For one, he said it's possible they can cause a heat-related injury even without being in a hot environment. Moreover, they can make people become more active than they usually are, causing their body temperature to increase.
Other substances that might alter your cognition could present other issues. For instance, some might make you more drowsy or less oriented than usual, possibly causing you to fall asleep or remain under the sun for longer than you normally would.
While recreational drugs might be one concern, there are some medications that might also impact someone's sensitivity to heat. According to New Brunswick Public Health, there are several medications you should modify how you take if you're spending time outside in the heat:
Common medications including some antihistamines (like Benadryl), over-the-counter sleeping pills and anti-diarrhea pills
Psychiatric drugs like chlorpromazine, thioridazine, perphenazine, fluphenazine and more
Anti-parkinson drugs like benztropine, biperiden, ethopropazine and more
Anti-depressants like amitriptyline, doxepine, clomipramine and more
There's no doubt summer festivals are exciting events that draw thousands of people in, but there are certain risks festivalgoers must be aware of before they head out in the sun for the day. During Osheaga 2023 at Montreal's Parc Jean-Drapeau, paramedics responded to a dozen cases, four of which required hospitalization, according to the Canadian Press.
Howlett noted even though someone might be young and healthy, they shouldn't automatically believe they're immune to heat-related health problems. Still, he said festivals with prolonged days or multi-day events likely aren't the best places to bring young children or seniors. Either way, he urged people to practice "common sense things" like not leaving your children in unshaded areas for long amounts of time and instead take precautions when heading outside.
"Dehydration, heat exhaustion, progressing to more serious states, it's a real thing. It's something you have to pay attention to," Howlett shared. "There's a reason why these major festivals hire ambulance services and paramedics to help. ... It's a big potential risk."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
6 minutes ago
- Associated Press
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval[1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases[2] to date in 2025. A Measles holiday warning has been issued in the UK this year[3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF)[4] . Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO[5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine[6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] press release
Yahoo
25 minutes ago
- Yahoo
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. BURNABY, British Columbia, July 30, 2025--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes1. This highlights a broad need for support across both types of diabetes for insulin therapy optimization. This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario†,2 for people on insulin through the following programs: Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they: Live in a long-term care home, home for special care, or Community Home for Opportunity Are 24 or under without private insurance (OHIP+) Receive professional home and community care Get benefits from Ontario Works or ODSP Are enrolled in the Trillium Drug Program Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria. Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin. Non-Insured Health Benefits (NIHB) – for eligible First Nations and Inuit clients on insulin. "This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom's life-changing CGM technology," says André Côté, Vice President and General Manager of Dexcom Canada. "By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists‡, 3 for the management of insulin-using patients." Dexcom G7 is the most accurate CGM with clinically proven outcomes§,2 including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin. "As an endocrinologist, I've seen firsthand how continuous glucose monitoring has transformed diabetes management," says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. "Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical." Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time. Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle: Predictive Urgent Low Soon|| alert that can warn in advance of severe hypoglycemia9 Delay 1st High alert after a meal that may help reduce insulin stacking10,11 Waterproof sensor¶ Fast 30-minute sensor warm-up time Multiple sensor wear locations# Direct to Apple Watch functionality**– user can see glucose numbers right on their wrist As the #1 patient recommended CGM in Canada††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management. To learn more about Dexcom G7 and the public and private coverage options available, please visit About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR _______________________________________ * For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit † Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions. ‡ Based on a survey of Canadian Endocrinologists (n=41) § When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. || Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. ¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. # Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. ** Smart device sold separately. To view a list of compatible devices, visit Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. †† Based on a comparison in NPS scores across major CGM brands 1 2 Dexcom, data on file, 2025 3 Q&A, Dexcom Canadian Endos Report Wave 1 2024 4 Beck, RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Dexcom G7 User Guide. 10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255. 11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158. 12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024 View source version on Contacts Media Contact: Cole DouglasCdouglas@ 416.460.5480 Investor Contact: investor-relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNN
2 hours ago
- CNN
Food assistance benefits are tied to slower cognitive decline in older adults, new study suggests
For older adults who may otherwise be food-insecure, participating in food assistance benefits may be associated with a slower cognitive decline as they age, according to new research. Compared with eligible people who were not participating in the US Supplemental Nutritional Assistance Program, SNAP participants showed a slower decline in cognitive function during a 10-year period, essentially maintaining up to three additional years of cognitive health, according to the study presented Wednesday at the Alzheimer's Association International Conference in Toronto. 'We expected that SNAP might be protective for cognitive health based on prior research linking food insecurity to faster cognitive decline. But what did surprise us was the persistence of the effect over a decade — and the fact that the benefit was equivalent to preserving two to three extra years of cognitive health,' Linlin Da, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, said in an email. 'This study is important because it shows that supporting basic needs like food access can have long-term benefits for brain health, something not widely recognized,' Da said. 'In a time when we're seeking ways to delay or prevent Alzheimer's disease and related dementia, this suggests that public health and social policy can play a role alongside medical approaches.' It's estimated that nearly 37% of SNAP participants are in households with older adults or people with disabilities, and on average, SNAP participants may receive an estimated $6.16 per day per person in benefits. SNAP, known previously as the Food Stamp Program, helped an average of more than 41 million low-income people in the United States in a typical month last year, according to the Center on Budget and Policy Priorities. Now, President Trump's One Big Beautiful Bill Act makes the largest cuts to food stamps in the program's 86-year history, jeopardizing assistance for millions of people. The nonpartisan Congressional Budget Office estimates that the law will reduce federal spending on SNAP by almost $187 billion over the next decade. Some public health experts worry that while cuts to SNAP would lead to budgetary savings, it also could produce higher rates of food insecurity and poorer health outcomes in the long run, according to the nonprofit KFF, formerly known as the Kaiser Family Foundation. And some Democratic state leaders are warning about potential consequences. 'During a time when many American families are already struggling, food assistance programs such as SNAP are more essential than ever,' Illinois Gov. JB Pritzker said in a news release Tuesday. 'Under the veneer of 'cost savings,' the Trump Administration is slashing benefits and threatening the well-being of hundreds of thousands of Illinoisans, putting their health and welfare at risk. Our state deserves better.' The researchers on the new study, from the University of Georgia, analyzed data on more than 2,000 adults 50 and older across the United States. About half of them were enrolled in SNAP in 2010, and the other half were eligible for SNAP but did not participate in the program. Every two years between 2010 and 2020, the researchers interviewed the study participants to assess their cognition, memory and executive function, including their ability to carry out tasks or to plan. Each person was given a cognitive score based on the assessments. The assessments, which have not yet been published in a peer-reviewed journal, showed that those enrolled in SNAP had a slower rate of cognitive decline in cognition, memory and executive function during the 10-year period. 'The decline in global cognitive function was 0.10 points slower per year for SNAP participants compared to nonparticipants,' Da said. 'While that may sound small, over a 10-year period, this adds up to about one full point of preserved cognition. To put it in clinical terms, this slower decline could delay the onset of mild cognitive impairment by nearly a decade for someone starting at a healthy cognitive baseline.' When the researchers analyzed their data by race and ethnicity, they found that there was a slightly faster decline in cognition and memory among Black and Hispanic adults compared with White adults, but no significant racial differences were observed for executive function. However, SNAP participation was linked with much stronger cognitive benefits and slower decline among the White adults. As a 10-year study, the new research covers 'a good length of time' to determine the benefits of diet and SNAP as associated with cognitive health, Dr. Shae Datta, a neurologist at NYU Langone Health and brand partner for the supplement company Qunol, said in an email. 'Having the means to buy nutritious food is important for preventing cognitive decline,' said Datta, who was not involved in the new study. 'This study suggested that SNAP participation, or any nutritional support program can delay the onset of cognitive impairment or dementia. Translating in a greater ability to manage their activities of daily living and remain independent longer.' While the new study suggests only an association between SNAP participation and cognitive decline, rather than a causal relationship, the researchers emphasized that not having adequate access to food can negatively affect cognitive function. SNAP participation may help improve someone's nutritional intake, thus potentially slowing cognitive decline. 'When people don't have access to healthy nutrition programs, they may have inadequate intake of, for example, brain healthy fats, omega-3 fatty acids, which are found in fish, fish like lake trout, mackerel, herring, albacore tuna, sardines and wild salmon,' said preventive neurologist Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida, who was not involved in the new study. 'Having a balanced diet can neutralize a lot of the risk elements related to developing cognitive decline. The way that I would think about this is, the Mediterranean-style diet is by far the most evidence-based when it comes to reducing the risk of cognitive decline,' Isaacson said. 'But a Mediterranean-style diet is rich in green, leafy vegetables. Vegetables are expensive. Fatty fish are expensive. So nutrition assistance programs can really fill the gap.' A Mediterranean-style diet includes mostly vegetables, fruits, beans, nuts, lentils, whole grains and healthy fats, such as extra virgin olive oil and avocados. The diet may include a moderate amount of natural cheese and yogurt, but it is low in red meat and sugar. Overall, the potential health benefits of participating in a food assistance program for an older adult who otherwise would be food-insecure are based on whether that adult uses the program to access brain healthy foods while taking other steps to maintain cognitive health, said Isaacson, who established one of the first Alzheimer's prevention clinics in the United States. 'You can't eat a magic blueberry and think you're going to prevent Alzheimer's disease,' he said. 'Healthy nutrition, exercising on a regular basis, seeing a doctor regularly to control blood pressure, cholesterol, diabetes, vascular risk factors – you need to do all of these different things to have the most benefit.' CNN's Nathaniel Meyersohn contributed to this report.